<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5661">
  <stage>Registered</stage>
  <submitdate>12/09/2013</submitdate>
  <approvaldate>12/09/2013</approvaldate>
  <nctid>NCT01943799</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B</studytitle>
    <scientifictitle>A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-330-0101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic HBV Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - GS-4774
Treatment: drugs - OAV Regimen

Experimental: OAV Alone - Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.

Experimental: OAV + GS-4774 2 YU - Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.

Experimental: OAV + GS-4774 10 YU - Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.

Experimental: OAV + GS-4774 40 YU - Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.


Other interventions: GS-4774
GS-4774 2, 10, or 40 YU administered as a subcutaneous injection every 4 weeks for a total of 6 doses

Treatment: drugs: OAV Regimen
Oral antiviral (OAV) regimen as administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in log10 IU/mL serum hepatitis B surface antigen (HBsAg) from Baseline to Week 24</outcome>
      <timepoint>Baseline to Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in log10 IU/mL serum HBsAg from Baseline to Weeks 12 and 48</outcome>
      <timepoint>Baseline to Weeks 12 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HBsAg loss and HBsAg seroconversion at Weeks 24 and 48</outcome>
      <timepoint>Weeks 24 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with hepatitis B e antigen (HBeAg) loss and HBeAg seroconversion at Weeks 24 and 48</outcome>
      <timepoint>Weeks 24 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with a 1-log decline in HBsAg at Weeks 12, 24, and 48</outcome>
      <timepoint>Weeks 12, 24, and 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ability to understand and sign a written informed consent form, which must be obtained
             prior to initiation of study procedures

          -  Currently taking an HBV oral antiviral medication

          -  Documented evidence of chronic HBV infection (eg, HBsAg positive for more than 6
             months)

          -  Virally-suppressed (HBV DNA below the lower limit of quantification (LLOQ) by for = 1
             year)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Cirrhosis

          -  Inadequate liver function

          -  Co-infection with hepatitic C virus (HCV), HIV or hepatitic D virus (HDV)

          -  Evidence of hepatocellular carcinoma

          -  Significant cardiovascular, pulmonary, or neurological disease

          -  Females who are pregnant or may wish to become pregnant during the study

          -  Received solid organ or bone marrow transplant

          -  Use of another investigational agents within 3 months of screening

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with compliance

          -  History of demyelinating disease (Guillain-Barre), Bell's Palsy, Crohn's disease
             ulcerative colitis, autoimmune disease

          -  Known hypersensitivity to study drug, metabolites or formulation excipients

          -  Malignancy within 5 years prior to screening, with the exception of specific cancers
             that are cured by surgical resection (basal cell skin cancer, etc). Participants under
             evaluation for possible malignancy are not eligible.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>178</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and efficacy of GS-4774 in adults with chronic hepatitis
      B (CHB) viral infection who have been virally suppressed with an oral antiviral medication.
      Participants will be randomized in a 1:2:2:2 ratio to the treatment arms for 20 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01943799</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Benedetta Massetto, MD, PhD</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>